Table 9.
Phase II trials (with results) of molecular targets in gynecological cancers
| ID | Cancer/condition | No. | Target | Intervention | ORR (%) | mPFS (mon.) | mOS (mon.) | SAEs (%) | Refs |
|---|---|---|---|---|---|---|---|---|---|
| NCT01936363 | OC | 63 | MEK | (1) Pimasertib + XL765 | 12.5 | 9.99 | – | 50 | * |
| (2) Pimasertib + placebo | 12.1 | 12.71 | 56.25 | ||||||
| NCT00551070 | OC/recurrent, low-grade serous | 52 | Selumetinib | 15 | – | – | 63.46 | 298 | |
| NCT01011933 | EC/recurrent or persistent | 54 | Selumetinib | 6 | 2.3 | 8.5 | 64 | 297 | |
| NCT02538627 | CC/recurrent or persistent | 35 | Trametinib + Uprosertib | 7.1 | 3.6 | 14.8 | 57 | 202 | |
| NCT01935973 | EC/ recurrent or persistent | 26 | Trametinib + Uprosertib | 8.3 | PFS at 6 months = 14% | 61 | 203 | ||
| NCT01047891 TRIAS | OC/platinum-resistant recurrent | 185 | Raf | (1) Sorafenib + topotecan | 31 | 6.7 | 17.1 | 59 | 290 |
| (2) Placebo + topotecan | 12 | 4.4, P = 0.0018 | 10.1, P = 0.017 | 51 | |||||
| NCT00390611 | OC/first-line treatment | 85 | (1) Sorafenib + PC | 69 | 15.4 | 36.5 | 27.91 | 288 | |
| (2) PC | 74 | 16.3, P = 0.38 | Not reached | 23.81 | |||||
| NCT00096200 | OC/platinum-sensitive recurrent | 36 | (1) Sorafenib + PC | 61 | 16.8 | 25.9 | 21.43 | 291 | |
| (2) Sorafenib | 15 | 5.6, P = 0.012 | 25.6, P = 0.974 | 16.67 | |||||
| NCT00791778 | OC/maintenance | 246 | (1) Sorafenib | – | 12.7 | – | 21.14 | 289 | |
| (2) Placebo | 15.7 | 20.33 | |||||||
| NCT00093626 | OC/third-line therapy | 11 | Sorafenib | – | 2.00 | 11.78 | low | 286 | |
| NCT00436215 | OC/recurrent | 55 | Sorafenib + bevacizumab | 19 | 6.1 | 45.45 | * | ||
| NCT00281515 | OC/stage IIb–IV | 105 | Ras | (1) Lonafarnib + PC | – | 11.5 | 20.6 | – | 278 |
| (2) PC | 16.4, P = 0.0141 | 43.4, P = 0.012 | |||||||
| NCT01164995 M10MKO | OC/p53 mutated refractory | 21 | Wee1 | Adavosertibc (AZD1775) | 43 | 5.3 | 12.6 | – | 341 |
| NCT01039207 | OC/recurrent or persistent | 31 | c-MET | Rilotumumab | 3.2 | PFS at 6 months = 6.5% | 45.16 | 322 | |
| NCT01716715 | OC/recurrent | 111 | (1) Cabozantinib | 7 | 5.3 | 19.4 | – | 324 | |
| (2) Paclitaxel | 24.1 | 5.5 | Not reached | ||||||
| NCT02315430 NRG-GY001 | OC/recurrent | 13 | Cabozantinib | 0 | 3.6 | 8.1 | – | 323 | |
| NCT00940225 | OC | 70 | Cabozantinib | 15 | 4.9 | – | 74.5 | 433 | |
| NCT02059265 | OC/ recurrent or persistent | 35 | Src | Dasatinib | 3.6 | 2.1 | 17.7 | 57.14 | 331 |
| NCT01196741 | OC/platinum-resistant recurrent | 107 | (1) Saracatinib + placitaxel | 29 | 4.7 | – | 57.97 | 434 | |
| (2) Placebo + placitaxel | 43 | 5.3, P = 0.99 | 51.43 | ||||||
| NCT01175343 | OC/platinum-resistant recurrent | 45 | Notch | RO4929097 | 0 | 1.3 | – | 22.73 | 339 |
*Unpublished data found in ClinicalTrials.gov